Highlights
- Metro-Pancreas combines tumor size and CA 19-9 to stratify prognosis in resectable pancreatic ductal adenocarcinoma (PDAC).
- After neoadjuvant chemotherapy (NAT), Metro-Pancreas restaging improves prognostic discrimination and enables dynamic risk reassessment.
- Reclassification from Metro-Pancreas OUT to IN post-NAT is associated with significantly improved postoperative disease-free and overall survival.
- Integration of Metro-Pancreas with other prognostic indicators may optimize personalized treatment planning in resectable PDAC.
Background
Specialty calculators
For clinical reference; use professional judgment.
